Searched for
ABBOTT PHARMA
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 36%Whether you are a trader or an investor, there is one thing to watch carefully in the coming days: Earnings. The reason why this is importa...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%Despite the US and Iran failing to reach an agreement over the weekend, the street is not entirely in a bearish mood. Market breadth is not...
- Abbott picks public policy chief in IndiaMore pharma companies are said to be engaging with the government in the aftermath of Covid 19, according to industry experts.
- AstraZeneca Pharma, Abbott Healthcare terminate distribution agreements for diabetes drug in IndiaAstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapaglifl...
- Abbott looking for buyer to sell low-end brandsFor drug companies in India, the last two years have been one of the most challenging periods as frequent price cuts and ban have dented th...
- Pfizer, Abbott shares tank after ban on Corex, Phensedyl and 327 other drugsAbbott India shares fell 1.98 per cent to hit a low of Rs 4,755 after ban on its Phensedyl syrup. Abbott is reviewing the notification, the...
- Pick-up in local market boosts pharma MNCsA pick-up in the local pharma market augurs well for MNCs which are still recovering from the adverse impact of drug price control on high-...
- Abbott Laboratories upbeat about Indian pharma marketAbbott, one of the top 10 drug makers in the world, made a splash when it bought the generic business of Piramal Healthcare for Rs 17,000 c...
- Top three pharma MNCs Novartis, Pfizer and Abbott lose 10% in 2013Most MNCs have been facing heat due to fast expiring patents, challenges in new drug discovery and depleting product pipeline.
- Pharma MNCs run into rough weatherThe rejection of the Glivec patent has added to pharma MNCs’ woes after a slew of measures in the past one year.
- Abbott Laboratories set to consolidate India operationsThe $39-bn pharma giant Abbott Labs will consolidate India operations under a new leadership, as part of a plan to tap operational synergie...
- India's low rate of diagnosis and disease awareness presents a great opportunity to grow: Abbott IndiaNutrition is another focus area for the US-based pharma company, one of the market leaders in nutrition products with brands such as Pedias...
- Low diagnostics rate, Nutrition are the focus areas: Abbott IndiaIndia’s low rate of diagnosis and disease awareness present ample opportunity for drugmakers to do more in the country
- Dishman Pharma likely to get $40 mn from Abbott & MerckAccording to sources, the company officials met Abbott & Merck last week. Abbott & Merck are expected to come for plant inspection next mon...
- Small drug cos on anti-buyout driveConcerned about the recent spate of takeovers of domestic pharma firms by MNCs, small and medium players in the sector have decided to appr...
- Abbott makes open offer for 20 pc in Solvay Pharma IndiaUS-based pharmaceutical firm Abbott Laboratories announced completing the acquisition of the global drug business of Solvay SA, consequent ...
- Abbott to acquire Solvay Pharmaceuticals for $ 6.6 bnUS healthcare major Abbott Laboratories will buy pharma business of Belgium-based Solvay Group for USD 6.6 billion.
- Lupin reaches out-of-court settlement with Abbott on OmnicefDomestic pharma company Lupin has reached an out-of-court settlement with US pharma major Abbott and Japan’s Astellas Pharma for the market...
- Wockhardt challenges patents litigationWockhardt Pharma has just got into the game. The co is challenging Abbott Lab patent on epilepsy drug.
Load More
